Antidiarrhoeal

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Retrieved on: 
Monday, June 6, 2022

Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.

Key Points: 
  • Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.
  • We are very pleased with the updated activity seen with the combination of neratinib plus trastuzumab plus fulvestrant therapy in this heavily pretreated metastatic breast cancer patient population with HER2-mutated disease.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.

Global Gastrointestinal Drugs Market Report 2022: Focus on Antacids, Antiulcerants, Antiobesity, Antiemetics and Antinauseants, & Antidiarrhoeals - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022

The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.

Key Points: 
  • The global gastrointestinal drugs market is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%.
  • The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome.
  • The main types of gastrointestinal drugs are antacids, antiulcerants, antiobesity, antiemetics and antinauseants and antidiarrhoeals.
  • During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs.

Gastrointestinal Drugs Global Market Opportunities and Strategies to 2030: Focus on Antacids, Antiulcerants, Antiemetics, Antinauseants and Antidiarrheals - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022

The global gastrointestinal drugs market reached a value of nearly $46,679.8 million in 2020, having increased at a CAGR of 4.9% since 2015.

Key Points: 
  • The global gastrointestinal drugs market reached a value of nearly $46,679.8 million in 2020, having increased at a CAGR of 4.9% since 2015.
  • The gastrointestinal drugs market is segmented by type into antacids, antiulcerants, antiemetics and antinauseants, antidiarrheals, and others.
  • The antiulcerants were the largest segment of the gastrointestinal drugs market segmented by type, accounting for 51.2% of the total in 2020.
  • It places the market within the context of the wider gastrointestinal drugs market; and compares it with other markets.

Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting

Retrieved on: 
Friday, December 10, 2021

For patients treated with CDK4/6 inhibitors without seeing tumor reversal, combination therapy with neratinib, fulvestrant and trastuzumab presents a promising new treatment option, said Dr. Jhaveri.

Key Points: 
  • For patients treated with CDK4/6 inhibitors without seeing tumor reversal, combination therapy with neratinib, fulvestrant and trastuzumab presents a promising new treatment option, said Dr. Jhaveri.
  • Alan H. Auerbach, Chief Executive Officer and President of Puma, added, We are pleased to see the activity of neratinib in both the hormone receptor-positive and triple negative breast cancer cohorts of the SUMMIT trial.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .